UA94231C2 - Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли - Google Patents

Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли

Info

Publication number
UA94231C2
UA94231C2 UAA200714106A UAA200714106A UA94231C2 UA 94231 C2 UA94231 C2 UA 94231C2 UA A200714106 A UAA200714106 A UA A200714106A UA A200714106 A UAA200714106 A UA A200714106A UA 94231 C2 UA94231 C2 UA 94231C2
Authority
UA
Ukraine
Prior art keywords
treating
composition
oligonucleotides
same
cell neoplasm
Prior art date
Application number
UAA200714106A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ли-ин Ван
Му-шен Бао
Юн-ли Юй
Original Assignee
Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чанчунь Хуапу Байотекнолоджи Ко., Лтд. filed Critical Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Publication of UA94231C2 publication Critical patent/UA94231C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение относится к способу лечения у млекопитающего В-клеточной опухоли и предусматривает введение эффективного количества композиции, которая содержит олигонуклеотид, который отвечает последовательности SEQ ID NO: 1.
UAA200714106A 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли UA94231C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2005100695764A CN1865275B (zh) 2005-05-17 2005-05-17 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸

Publications (1)

Publication Number Publication Date
UA94231C2 true UA94231C2 (ru) 2011-04-26

Family

ID=37424439

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200714106A UA94231C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
UAA200714103A UA91057C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200714103A UA91057C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Country Status (22)

Country Link
US (3) US8133874B2 (ru)
EP (2) EP1883411B1 (ru)
JP (2) JP4837033B2 (ru)
KR (2) KR101294131B1 (ru)
CN (1) CN1865275B (ru)
AU (2) AU2006246898B2 (ru)
BR (2) BRPI0609882A2 (ru)
CA (2) CA2609062C (ru)
CY (1) CY1114844T1 (ru)
DK (2) DK1883411T3 (ru)
ES (2) ES2442462T3 (ru)
HK (2) HK1112745A1 (ru)
IL (2) IL187249A (ru)
MX (2) MX2007014145A (ru)
NZ (1) NZ563582A (ru)
PL (2) PL1883647T3 (ru)
PT (2) PT1883411E (ru)
RU (2) RU2413519C2 (ru)
SI (2) SI1883411T1 (ru)
UA (2) UA94231C2 (ru)
WO (2) WO2006122463A1 (ru)
ZA (2) ZA200710311B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182880A1 (en) * 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
CN101643496B (zh) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
WO2010053433A1 (en) * 2008-11-04 2010-05-14 Index Pharmaceuticals Ab Increased expression of specific antigens
DK3165607T3 (da) * 2010-12-21 2021-05-31 Index Pharmaceuticals Ab Biologisk aktive oligonukleotider, der kan modulere immunsystemet
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
CN106893724B (zh) * 2015-12-17 2023-05-02 苏州派动生物技术有限公司 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
AU8729101A (en) * 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
ATE440618T1 (de) * 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE10258677A1 (de) 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
CN100486987C (zh) * 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
CN100439386C (zh) * 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
EP2264046B1 (en) 2003-07-25 2011-11-09 Changchun Huapu Biotechnology Co., Ltd. Artificial CpG single-stranded oligodeoxynucleotide and antiviral use thereof
JP4513879B2 (ja) 2008-03-05 2010-07-28 ソニー株式会社 像ぶれ補正装置、レンズ鏡筒装置及びカメラ装置

Also Published As

Publication number Publication date
BRPI0609882A2 (pt) 2010-05-04
EP1883647A4 (en) 2010-10-06
RU2007146706A (ru) 2009-06-27
ZA200710312B (en) 2009-08-26
US20120142761A1 (en) 2012-06-07
WO2006122464A1 (en) 2006-11-23
KR101294131B1 (ko) 2013-08-07
UA91057C2 (ru) 2010-06-25
AU2006246897A1 (en) 2006-11-23
IL187249A0 (en) 2008-02-09
RU2007146705A (ru) 2009-06-27
EP1883647B1 (en) 2013-10-23
HK1113318A1 (en) 2008-10-03
US8450292B2 (en) 2013-05-28
MX2007014146A (es) 2008-03-07
CA2609062A1 (en) 2006-11-23
PT1883647E (pt) 2014-01-20
KR20080011426A (ko) 2008-02-04
US20090202567A1 (en) 2009-08-13
SI1883647T1 (sl) 2014-02-28
DK1883647T3 (da) 2014-01-27
NZ563582A (en) 2010-04-30
ZA200710311B (en) 2009-08-26
EP1883411A4 (en) 2010-10-06
PL1883647T3 (pl) 2014-03-31
ES2442462T3 (es) 2014-02-11
US8133874B2 (en) 2012-03-13
AU2006246898B2 (en) 2011-08-18
AU2006246897B2 (en) 2012-04-12
CN1865275B (zh) 2011-06-15
CY1114844T1 (el) 2016-12-14
PT1883411E (pt) 2013-11-11
IL187249A (en) 2012-03-29
MX2007014145A (es) 2008-03-07
AU2006246898A1 (en) 2006-11-23
JP4837034B2 (ja) 2011-12-14
JP4837033B2 (ja) 2011-12-14
PL1883411T3 (pl) 2014-01-31
RU2413519C2 (ru) 2011-03-10
US20090162279A1 (en) 2009-06-25
CA2609067A1 (en) 2006-11-23
CA2609062C (en) 2013-11-19
BRPI0609885A2 (pt) 2010-05-04
KR101346716B1 (ko) 2014-01-02
SI1883411T1 (sl) 2014-01-31
EP1883647A1 (en) 2008-02-06
WO2006122463A1 (en) 2006-11-23
DK1883411T3 (da) 2013-11-18
CN1865275A (zh) 2006-11-22
JP2008539768A (ja) 2008-11-20
IL187281A (en) 2012-04-30
HK1112745A1 (en) 2008-09-12
RU2409672C2 (ru) 2011-01-20
EP1883411B1 (en) 2013-08-14
IL187281A0 (en) 2011-08-01
KR20080007655A (ko) 2008-01-22
JP2008539767A (ja) 2008-11-20
EP1883411A1 (en) 2008-02-06
ES2433129T3 (es) 2013-12-09

Similar Documents

Publication Publication Date Title
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
TW200637522A (en) Skin treatment articles and methods
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
WO2009014903A3 (en) Colouring solution for dental ceramic articles and related methods
TW200501277A (en) Nanofiber surfaces for use in enhanced surface area applications
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
WO2001081417A3 (en) Use of taci as an anti-tumor agent
WO2006128089A3 (en) Compositions and methods for treating tissue
WO2005116252A3 (en) Methods for evaluating ribonucleotide sequences
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008088724A3 (en) Modified endoglucanase ii and methods of use
GEP20135915B (en) Trazodone and trazodone hydrochloride in purified form
EP1773363A4 (en) NGNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
MX2007000364A (es) Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.
MX2010010177A (es) Fragmentos de beta timosina mejorada.
MX2010001496A (es) Colorantes dispersos, su preparacion y uso.
WO2010068907A3 (en) Compositions of proton pump inhibitors and insulin secretagogues, kits and methods of their use to treat diabetes
WO2007035755A3 (en) Methods of treating hematological malignancies